Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.3    
    

	 
	 	 

	REGISTERED	 	REGISTERED

Ill.
C. C. No. 6226 

        THIS
NOTE IS A GLOBAL NOTE REGISTERED IN THE NAME OF THE DEPOSITARY (REFERRED TO HEREIN) OR A NOMINEE THEREOF AND, UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE FOR THE INDIVIDUAL NOTES
REPRESENTED HEREBY AS PROVIDED IN THE INDENTURE REFERRED TO BELOW, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY
TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH SUCCESSOR DEPOSITARY. UNLESS THIS NOTE IS PRESENTED BY AN
AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (55 WATER STREET, NEW YORK, NEW YORK), TO THE TRUSTEE FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS
REGISTERED IN THE NAME OF CEDE & CO. OR SUCH OTHER NAME AS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY AND ANY PAYMENT IS MADE TO CEDE & CO., ANY TRANSFER,
PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 

UNION
ELECTRIC COMPANY

5.25% SENIOR SECURED NOTE DUE 2012 

	CUSIP: 906548BX9	 	NUMBER: 1
	

ORIGINAL ISSUE DATE: August 22, 2002	
 	

PRINCIPAL AMOUNT: $173,000,000
	

INTEREST RATE: 5.25%	
 	

MATURITY DATE: September 1, 2012

        UNION ELECTRIC COMPANY, a corporation of the State of Missouri (the "COMPANY"), for value received hereby promises to pay to CEDE & CO. or registered
assigns, the principal sum of ONE HUNDRED SEVENTY THREE MILLION DOLLARS ($173,000,000) on the Maturity Date set forth above, and to pay interest thereon from August 22, 2002 or from the most
recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually in arrears on the March 1 and September 1 in each year, commencing
March 1, 2003, at the per annum Interest Rate set forth above, until the principal hereof is paid or made available for payment. No interest shall accrue on the Maturity Date, so long as the
principal amount of this Note is paid on the Maturity Date. The interest so payable and punctually paid or duly provided for on any such Interest Payment Date (except for interest payable on the
Maturity Date set forth above or, if applicable, upon redemption or acceleration) will, as provided in the Indenture (as defined below), be paid to the Person in whose name this Note is registered at
the close of business on the Regular Record Date for such interest, which shall be the February 15 or August 15, as the case may be, next preceding such Interest Payment Date; provided
that the first Interest Payment Date for any part of this Note, the Original Issue Date of which is after a Regular Record Date but prior to the applicable Interest Payment Date, shall be the Interest
Payment Date following the next succeeding Regular Record Date; and provided that interest payable on the Maturity Date set forth above or, if applicable, upon redemption or acceleration, shall be
payable to the Person to whom principal shall be payable. Except as otherwise provided in the Indenture, any such interest not so punctually paid or duly provided for shall forthwith cease to be
payable to the Holder on such Regular Record Date and shall be paid to the Person in whose name this Note is registered at the close of business on a Special Record Date for the payment of such
defaulted interest to be fixed by the Trustee, notice whereof shall be given to Noteholders not more than fifteen days or fewer than ten days prior to such Special Record Date. Payment of the
principal of and interest and premium on this Note shall be payable pursuant to Section 2.12(a) of the Indenture. 

 

        This
Note is a Global Note in respect of a duly authorized issue of 5.25% Senior Secured Notes due 2012 (the "NOTES OF THIS SERIES", which term includes any Global Notes representing
such Notes) of the Company issued and to be issued under an Indenture dated as of August 15, 2002, between the Company and The Bank of New York, as trustee (the "TRUSTEE", which term includes
any successor Trustee under the Indenture) and indentures supplemental thereto (collectively, the "INDENTURE"). Under the Indenture, one or more series of notes may be issued and, as used herein, the
term "Notes" refers to the Notes of this Series and any other outstanding series of Notes. Reference is hereby made to the Indenture for a more complete statement of the respective rights, limitations
of rights, duties and immunities thereunder of the Company, the Trustee and the Noteholders and of the terms upon which the Notes are and are to be authenticated and delivered. This Note has been
issued in respect of the series designated on the first page hereof in the aggregate principal amount of $173,000,000. 

        Prior
to the Release Date (as hereinafter defined), the Notes will be secured by first mortgage bonds (the "SENIOR NOTE FIRST MORTGAGE BONDS") delivered by the Company to the Trustee for
the benefit of the Holders of the Notes, issued under the Indenture of Mortgage or Deed of Trust, dated June 15, 1937, from the Company to The Bank of New York, as successor trustee (the
"MORTGAGE TRUSTEE"), as supplemented and modified (collectively, the "FIRST MORTGAGE"). Reference is made to the First Mortgage and the Indenture for a description of the rights of the Trustee as
holder of the Senior Note First Mortgage Bonds, the property mortgaged and pledged, the nature and extent of the security and the rights of the holders of first mortgage bonds, under the First
Mortgage and the rights of the Company and of the Mortgage Trustee in respect thereof, the duties and immunities of the Mortgage Trustee and the terms and conditions upon which the Senior Note First
Mortgage Bonds are secured and the circumstances under which additional first mortgage bonds may be issued. 

        From
and after such time as all first mortgage bonds (other than Senior Note First Mortgage Bonds) issued under the First Mortgage have been retired through payment, redemption or
otherwise at, before or after the maturity thereof (the "Release Date"), the Senior Note First Mortgage Bonds shall cease to secure the Notes in any manner. In certain circumstances prior to the
Release Date as provided in the Indenture, the Company is permitted to reduce the aggregate principal amount of a series of Senior Note First Mortgage Bonds held by the Trustee, but in no event prior
to the Release Date to an amount less than the aggregate outstanding principal amount of the series of Notes initially issued contemporaneously with such Senior Note First Mortgage Bonds. 

        Each
Note of this Series shall be dated and issued as of the date of its authentication by the Trustee and shall bear an Original Issue Date. Each Note issued upon transfer, exchange or
substitution of such Note shall bear the Original Issue Date of such transferred, exchanged or substituted Note, as the case may be. 

        All
or a portion of the Notes of this Series may be redeemed at the option of the Company at any time or from time to time. The redemption price for the Notes of this Series to be
redeemed on any redemption date will be equal to the greater of: (a) 100% of the principal amount of the Notes of this Series being redeemed on the redemption date; or (b) the sum of the
present values of the remaining scheduled payments of principal and interest on the Notes of this Series being redeemed on that redemption date (not including any portion of any payments of interest
accrued to the redemption date) discounted to the redemption date on a semiannual basis at the Adjusted Treasury Rate (as defined below) plus 20 basis points, as determined by the Reference Treasury
Dealer (as defined below); plus, in each case, accrued and unpaid interest thereon to the redemption date. Notwithstanding the foregoing, installments of interest on Notes of this Series that are due
and payable on Interest Payment Dates falling on or prior to a redemption date will be payable on the Interest Payment Date to the Holder of this Note as of the close of business on the relevant
Regular Record 

2

 

Date.
The redemption price will be calculated on the basis of a 360-day year consisting of twelve 30-day months. 

        The
Company shall mail notice of any redemption at least 30 days but not more than 60 days before the redemption date to each Holder of the Notes of this Series to be
redeemed. Unless the Company defaults in payment of the redemption price, on and after the redemption date, interest will cease to accrue on the Notes of this Series or portions thereof called for
redemption. 

        "ADJUSTED
TREASURY RATE" means, with respect to any redemption date, the rate per annum equal to the semiannual equivalent yield to maturity of the Comparable Treasury Issue, assuming a
price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date. 

        "COMPARABLE
TREASURY ISSUE" means the United States Treasury security selected by the Reference Treasury Dealer as having a maturity comparable to the remaining term of the Notes of this
Series to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to
the remaining term of such Notes of this Series. 

        "COMPARABLE
TREASURY PRICE" means, with respect to any redemption date, (A) the average of the Reference Treasury Dealer Quotations for such redemption date, after excluding the
highest and lowest such Reference Treasury Dealer Quotations, or (B) if the Trustee obtains fewer than three such Reference Treasury Dealer Quotations, the average of all such quotations, or
(C) if only one Reference Treasury Dealer Quotation is received, such quotation. 

        "REFERENCE
TREASURY DEALER" means (A) Banc of America Securities LLC or Credit Suisse First Boston Corporation (or their respective affiliates which are Primary Treasury Dealers),
and their
respective successors; provided, however, that if any of the foregoing shall cease to be a primary U.S. Government securities dealer in New York City (a "Primary Treasury Dealer"), the Company shall
substitute therefor another Primary Treasury Dealer; and (B) any other Primary Treasury Dealer(s) selected by the Trustee after consultation with the Company. 

        "REFERENCE
TREASURY DEALER QUOTATIONS" means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Trustee, of the bid and asked
prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Trustee by such Reference Treasury Dealer at 5:00 p.m. (New
York City time) on the third Business Day preceding such redemption date. 

        Interest
payments for this Note shall be computed and paid on the basis of a 360-day year of twelve 30-day months (and for any partial periods shall be calculated
on the basis of the number of days elapsed in a 360-day year of twelve 30-day months). If any Interest Payment Date or date on which the principal of this Note is required to
be paid is not a Business Day, then payment of principal, premium, if any, or interest need not be made on such date but may be made on the next succeeding Business Day with the same force and effect
as if made on such Interest Payment Date or date on which the principal of this Note is required to be paid and, in the case of timely payment thereof, no interest shall accrue for the period from and
after such Interest Payment Date or the date on which the principal of this Note is required to be paid. 

        The
Company, at its option, and subject to the terms and conditions provided in the Indenture, will be discharged from any and all obligations in respect of the Notes (except for certain
obligations including obligations to register the transfer or exchange of Notes, replace stolen, lost or mutilated Notes, maintain paying agencies and hold monies for payment in trust, all as set
forth in the Indenture) if the Company deposits with the Trustee money, U.S. Government Obligations which through the payment of interest thereon and principal thereof in accordance with their terms
will provide money, or a combination of money and U.S. Government Obligations, in any event in an amount sufficient, 

3

 

without
reinvestment, to pay all the principal of and any premium and interest on the Notes on the dates such payments are due in accordance with the terms of the Notes. 

        If
an Event of Default shall occur and be continuing, the principal of and interest on the Notes may be declared due and payable in the manner and with the effect provided in the
Indenture and, upon such declaration, the Trustee shall demand the redemption of the Senior Note First Mortgage Bonds to the extent provided in the Indenture. 

        The
Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modifications of the rights and obligations of the Company and the rights of the
Noteholders under the Indenture at any time by the Company and the Trustee with the consent of the Holders of not less than
a majority in principal amount of the outstanding Notes. Any such consent or waiver by the Holder of this Note shall be conclusive and binding upon such Holder and upon all future Holders of this Note
and of any Note issued upon the registration of transfer hereof or in exchange therefor or in lieu thereof whether or not notation of such consent or waiver is made upon this Note. 

        As
set forth in and subject to the provisions of the Indenture, no Holder of any Notes will have any right to institute any proceeding with respect to the Indenture or for any remedy
thereunder unless such Holder shall have previously given to the Trustee written notice of a continuing Event of Default with respect to such Notes, the Holders of not less than a majority in
principal amount of the outstanding Notes affected by such Event of Default shall have made written request and offered reasonable indemnity to the Trustee to institute such proceeding as Trustee and
the Trustee shall have failed to institute such proceeding within 60 days; provided that such limitations do not apply to a suit instituted by the Holder hereof for the enforcement of payment
of the principal of and any premium or interest on this Note on or after the respective due dates expressed here. 

        No
reference herein to the Indenture and to provisions of this Note or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay
the principal of and any premium and interest on this Note at the times, places and rates and the coin or currency prescribed in the Indenture. 

        As
provided in the Indenture and subject to certain limitations therein set forth, this Note may be transferred only as permitted by the legend hereto and the provisions of the
Indenture. 

        The
Indenture and the Notes shall be governed by, and construed in accordance with, the laws of the State of New York without regard to conflicts of law principles thereof. 

        Unless
the certificate of authentication hereon has been executed by the Trustee, directly or through an Authenticating Agent by manual signature of an authorized officer, this Note
shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. 

        All
terms used in this Note which are defined in the Indenture shall have the meanings assigned to them in the Indenture unless otherwise indicated herein. 

4

 

        IN
WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

	 	 	UNION ELECTRIC COMPANY
	

 	
 	

By:	
 	

/s/ WARNER L. BAXTER

	 	 	Title:	 	Senior Vice President

	 	 	Attest:	 	/s/ G.L. WATERS

	 	 	Title:	 	Assistant Secretary

	TRUSTEE'S CERTIFICATE

OF AUTHENTICATION	 	 	 	 
	

Dated: August 22, 2002	
 	

 	
 	

 
	

This Note is one of the Notes of the series herein designated, described or provided for in the within-mentioned Indenture.	
 	

 	
 	

 
	

The Bank of New York, As Trustee	
 	

 	
 	

 

	By:	 	/s/ ALBERT LUNDY
 Authorized Signatory

As Agent for

	 	 

5

 
ABBREVIATIONS

        The
following abbreviations, when used in the inscription on the face of this instrument, shall be construed as though they were written out in full according to applicable laws or
regulations: 

	TEN COM—as tenants in common	 	UNIF GIFT	 	 	 
	 	 	MIN ACT—	 	Custodian	 
	 	 	 	
 (Cust)	 	
 (Minor)
	TEN ENT—as tenants by the entireties	 	Under Uniform Gifts to Minors	 	 	 
	JT TEN—as joint tenants with right of survivorship and not as tenants in common	 	 	 	 	 
	 	 	
 State

Additional abbreviations may also be used

though not in the above list. 

FOR
VALUE RECEIVED the undersigned hereby sell(s),

assign(s) and transfer(s) unto 

PLEASE
INSERT SOCIAL SECURITY OR OTHER

IDENTIFYING NUMBER OF ASSIGNEE 

Please
print or typewrite name and address

including postal zip code of assignee 

	
 the within note and all rights thereunder, hereby irrevocably constituting and appointing attorney to transfer said note on the books of the Company, with full power of substitution in the premises.	 
	Dated:	 	 
	 	
	 
	 	 	
 NOTICE: The signature to this assignment must correspond with the name as written upon the face of the within instrument in every particular, without alteration or enlargement or any change
whatever.
	

 	

 	

Signature(s) must be guaranteed by a financial institution that is a member of the Securities Transfer Agents Medallion Program ("STAMP"), the Stock Exchange Medallion Program ("SEMP") or the New York Stock Exchange, Inc. Medallion Signature
Program("MSP").

6

QuickLinks

Exhibit 4.3employmentagmtrg

                             DNAPrint genomics, Inc.

                              EMPLOYMENT AGREEMENT

This Employment Agreement is made as of May 16, 2003 by and between DNAPrint
genomics, Inc, a Utah corporation (the "Company") having its principal place of
business at 900 Cocoanut Avenue, Sarasota, Fl 34234 and Richard Gabriel (the
"Executive") currently residing at 20 Blodgett Avenue, Swampscott, MA 01907.

                             BACKGROUND INFORMATION

The Company wishes to secure the employment services of the Executive for a
definite period of time and upon the particular terms and conditions hereinafter
set forth. The Executive is willing to be so employed. Accordingly, the parties
agree as follows:

                              OPERATIVE PROVISIONS

        1. EMPLOYMENT AND TERM:

The Company hereby employs Executive and the latter hereby accepts employment by
the Company for the one (1) year period commencing on May 16, 2003 (the
"Commencement Date") and expiring May 15, 2004, which employment shall be
automatically extended for unlimited successive one (1) year periods unless it
is terminated during the term of any such of any such period, whether initial or
extended, by the occurrence of one of the events described in Section 8. hereof,
or at the end of any such period (subject to extension by operation of the
disability provisions contained in Section 8.) by one party furnishing the other
with written notice, at least sixty (60) days prior to the expiration of such
period, of any intent to terminate this Agreement upon the expiration of such
period.

        2. DUTIES

During the term of this Agreement, whether initial or extended, the Executive
shall render to the Company services as Chief Executive Officer of the Company and
shall perform such duties as may be designated by and subject to the supervision
of the Company's Board of Directors, and shall serve in such additional
capacities appropriate to his responsibilities and skills as shall be designated
by the Board of Directors. During such period, the Executive shall devote his
full attention, time and energies as necessary to the business affairs of the
Company (subject to the terms of Section 4. below), and will use his reasonable
business efforts to promote the interests and reputation of the Company;
provided that he may pursue such non-competitive activities as do not interfere
with the complete performance of his obligations hereunder. Any question of
interpretation which may arise under the preceding provision shall be resolved
by majority decision of the Company's Board of Directors.

        3. COMPENSATION

For the services to be rendered by the Executive under this Agreement, the
Company shall pay him, while he is rendering such services and performing his
duties hereunder, and the Executive shall accept as full payment for such
service thirty (30) million shares of DNAPrint genomics, Inc. stock to be
issued as determined and set forth on Exhibit A hereto. In addition, the Company
shall pay to the Executive a cash bonus in the amount necessary to compensate
the Executive for any federal or state income tax payable on the stock
compensation granted hereunder, taking into account the additional tax payable
on the cash bonus provided hereby. Such cash bonus shall be paid by the Company
at the earliest time after such tax is incurred that the Board of Directors, in
its reasonable discretion, determines the Company can pay such bonus without
placing itself in a precarious cash position, but no later than the time at
which the Employee is required to pay the tax.

        4. VACATION: FRINGE BENEFITS: REIMBURSEMENT OF EXPENSES.

The Executive shall be entitled to four (4) weeks of fully paid vacation during
the initial and each extended term of this Agreement, which vacation is subject
to increase from time to time at the discretion of the Board of Directors. He

                            DNAPrint genomics, Inc.                         1
                     900 Cocoanut Ave., Sarasota, FL 34234

shall not be entitled to receive monetary or other valuable consideration for
vacation time to which he is entitled but does not take, unless so ordered by
the Board of Directors. Timing of vacations shall be at the sole discretion of
the Board of Directors, reasonably exercised so as not to unnecessarily
inconvenience the Executive.

During his period of employment hereunder, the Executive shall further be
entitled to (a) such leave by reason of physical or mental disability or
incapacity and to such participation in medical and life insurance, pension
benefits, disability and other fringe benefit plans as the Company may make
generally available to all of its executive employees and other employees from
time to time; subject, however, as to such plans, to such budgetary constraints
or other limitations as may be imposed by the Board of Directors of the Company
from time to time: and (b) reimbursement for all normal and reasonable expenses
necessarily incurred by him in the performance of his obligations hereunder,
subject to such reasonable substantiation requirements as may be imposed by the
Company to all employees of the Company, unless otherwise agreed to by the Board
of Directors.

        5. PROPRIETARY INTERESTS.

During or after the expiration of his term of employment with the Company, the
Executive shall not communicate or divulge to, or use for the benefit of, any
individual, association, partnership, trust, corporation or other entity except
the Company, any proprietary information of the Company received by the
Executive by virtue of such employment, without first being in receipt of the
Company's written consent to do so.

        6. RESTRICTIVE COVENANT.

During the term of his employment hereunder and for the two (2) year period
following the termination hereof for any reason other than (a) the Company's
discontinuance of activities; or (b) an adjudication of the Company's material
breach of any of its obligations set forth in Sections 1-4, inclusive, the
Executive shall not, directly or indirectly, engage in or become an owner of,
render any service to, enter the employment of, or represent or solicit for any
business which competes with any activity of the Company conducted at any time
during the Executive's period of employment and which is located in the United
States. The parties expressly agree that the duration and geographical area of
this restrictive covenant are reasonable.

This covenant shall be construed as an agreement independent of any other
provision herein; and the existence of any claim or cause of action of the
Executive against the Company regardless of how arising, shall not constitute a
defense to the enforcement by the Company of its terms. If any portion of the
covenant is held by a court to be unenforceable with respect either to its
duration or geographical area, for whatever reason, it shall be considered
divisible both as to time and geographical area, resulting in an intended
requirement that the longest lesser period of time or largest lesser
geographical area found by such court to be a reasonable restriction shall
remain an effective restrictive covenant, specifically enforceable against the
Executive.

Notwithstanding any statement contained in this Section 6, to the contrary,
legal or beneficial ownership by the Executive of a less than five percent (5%)
interest in a competitive corporation the stock of which is publicly traded on a
stock exchange or by means of an electronic dealer quotation system, shall not
of itself be deemed to constitute a breach by the Executive of the terms hereof.

        7. REMEDIES FOR BREACH OF EXECUTIVE OBLIGATIONS.

The parties to this agreement agree that the services of the Executive are of a
personal, specific, unique and extraordinary character and cannot be readily
replaced by the Company. They further agree that in the course of performing his
services, the Executive will have access to various types of proprietary
information of the Company, which, if released to others or used by the
Executive other than for the benefit of the Company, in either case without the
Company's written consent, could cause the Company to suffer irreparable injury.
Therefore, the obligations of the Executive established under section 5. and
section 6. hereof shall be enforceable both at law and in equity, by injunction,

                            DNAPrint genomics, Inc.                         2
                     900 Cocoanut Ave., Sarasota, FL 34234

specific performance, damages or other remedy; and the right of the Company to
obtain any such remedy shall be cumulative and not alternative and shall not be
exhausted by any one or more uses thereof.

        8. MODIFICATION AND TERMINATION

                a. Modification. This Agreement may be amended or modified only with the
                   mutual written consent of the parties, and in its present form
                   consists of the entire Agreement between and amongst the parties.

                b. Termination-General. This Agreement is subject to termination prior to
                   the expiration of its initial or any extended term, by the Company
                   upon the occurrence of any one of the following events: (a) the death
                   of the Executive; (b) the occurrence to Executive of a physical or
                   mental disability which, in the judgment (reasonably exercised) of the
                   Board of Directors, renders him unable to perform his normal duties on
                   behalf of the Company for a continuous period of six (6) months
                   (measured from the first day of the month immediately following the
                   occurrence of such disability); or (c) a determination by the Board of
                   directors that there is cause (as described in section d. below) to
                   terminate Executive's employment.

                c. By Death or Disability. In the event of the Executive's death, his
                   base compensation otherwise due for the succeeding period of time but
                   no less than three (3) full calendar months following his death shall
                   be paid to his designated beneficiary, or to his estate if no
                   beneficiary has been designated. In the event of his disability the
                   Executive shall be paid his compensation for the succeeding period of
                   time but no less than three (3) months. Thereafter for the succeeding
                   three (3) months shall be treated as being on an authorized but unpaid
                   leave of absence.

                d. For Cause. For purposes of this Agreement, the term "cause" shall
                   include, but not be limited to (i) the Executive's willful misconduct
                   or gross negligence; (ii) his conscious disregard of his obligations
                   hereunder or of any other duties reasonably assigned him by the Board
                   of Directors; (iii) his repeated conscious violation of any provision
                   of law, the Company's By-Laws or of its other stated polices,
                   standards, practices, regulations or procedures (iv) his commission of
                   any act involving moral turpitude; or (v) a determination that he has
                   demonstrated a dependence upon any addictive substance, including but
                   not limited to alcohol, controlled substances, narcotics or
                   barbiturates.

                e. Continued Effectiveness of Certain Obligations. No termination or
                   expiration of this Agreement, whether consummated by action of either
                   party or by operation of the terms hereof, shall relieve the Executive
                   from his continued performance of the obligations established under
                   Sections 5. and 6. hereof.

        9. INDEBTEDNESS OF EXECUTIVE. If, during the course of his employment,
           Executive becomes indebted to the Company for any reason, the Company
           shall, if it so elects, have the right to set off and to collect any sums
           due it from the Executive out of any amounts which it may owe to the
           Executive for unpaid compensation. In the event that this Agreement
           terminates for any reason, all sums owed by the Executive to the Company
           shall become immediately due and payable.

        10. MISCELLANEOUS PROVISIONS.

                            DNAPrint genomics, Inc.                         3
                     900 Cocoanut Ave., Sarasota, FL 34234

                a. Non-assignment: Neither this Agreement nor any right or interest
                   hereunder shall be assigned by the Executive, his Beneficiary or his
                   legal representatives.

                b. Enforcement: If any term or condition or this Agreement shall be
                   invalid or deemed unenforceable to any extent or in any application,
                   then the remainder of this Agreement, and such terms or conditions
                   except to such extent or in such application, shall not be affected
                   thereby, and each and every term and condition of this Agreement shall
                   be valid and enforced to the fullest extent and in the broadest
                   application permitted by law.

                c. Notice: All notices or other communications required or permitted to
                   be furnished pursuant to this Agreement shall be in writing and shall
                   be considered as properly furnished when actually received by the
                   recipient.

                d. Application of Florida Law: This Agreement, and the application or
                   interpretation thereof, shall be governed exclusively by its terms and
                   by the laws of the State of Florida. Venue shall be deemed located in
                   Sarasota County, Florida.

                e. Counterparts: This Agreement may be executed in any number of
                   counterparts, each of which shall be deemed an original, but all of
                   which together shall constitute on and the same instrument.

                f. Binding Effect: Each of the provisions and agreements herein contained
                   shall be binding upon and inure to the benefit of the personal
                   representatives, devisees, heirs, successors, transferees and assigns
                   of the respective parties hereto.

                g. Beneficiary: As used herein, the term "Beneficiary" shall mean the
                   person or persons (who may be designated contingently or successively
                   and who may be an entity other than an individual, including but not
                   limited to and estate or trust) designated on a written form
                   prescribed by the Board of Directors. Each Beneficiary designation
                   shall be effective only when filed with the Secretary of the Company
                   during the Executive's lifetime. Each Beneficiary designation filed
                   with the Secretary will cancel all designations previously so filed.

                   If the Executive fails to properly designate a Beneficiary or if the
                   Beneficiary predeceases the Executive, the Beneficiary shall be the
                   Executive's estate.

                h. Legal Fees and Costs: If a legal action is initiated by any party to
                   this Agreement against another, arising out of or relating to the
                   alleged performance or non-performance of any right or obligation
                   established hereunder, or any dispute concerning the same, any and all
                   fees, costs and expenses reasonably incurred by each successful party
                   in investigating, preparing for, prosecuting, defending against, or
                   providing evidence, producing documents or taking any other action in
                   respect of, such action shall be the joint and several obligation of
                   and shall be paid or reimbursed by the unsuccessful party.

          IN WITNESS WHEREOF, the parties have executed this Agreement.

DNAPrint genomics, Inc.

By: ___________________

                            DNAPrint genomics, Inc.                         4
                     900 Cocoanut Ave., Sarasota, FL 34234

                            DNAPrint genomics, Inc.

Title: _________________

________________________
Richard Gabriel

                            DNAPrint genomics, Inc.                         5
                     900 Cocoanut Ave., Sarasota, FL 34234

                            DNAPrint genomics, Inc.

                                    Exhibit A

Compensation:

The Executive will be awarded 30,000,000 shares of DNAPrint genomics, Inc.
common stock. The parties acknowledge that such shares have an approximate value
of $306,000 based on the following underlying assumptions:

        o The average closing price of the Company's common stock over the
          past 20 trading days was $0.017.

        o The application of a 40% discount to reflect lack of
          marketability is appropriate, yielding a per share valuation of
          $0.0102 per share.

        o Applying $0.0102 per share to 30,000,000 shares yields a
          valuation of $306,000.

Stock:

DNAPrint genomics, Inc. common stock will be issued and be subject to the normal
rules and regulations governing the issuance of stock of the Company and will
constitute restricted securities. However, upon registration of any stock, the
Company will include the Executive's stock in the registration.

Liability for Tax:

Except as explicitly required herein, the Company assumes no liability for the
tax consequences of this transaction. The Executive is fully responsible for all
tax, including but not limited to; federal, state, local or municipal tax.

Stock Legend:

The stock will bear an appropriate restrictive legend.

Name on Stock:

30,000,000 shares of DNAPrint genomics, Inc. stock is to be issued to:

                                Richard Gabriel
                                20 Blodgett Ave.
                              Swampscott, MA 01907

                            DNAPrint genomics, Inc.                         6
                     900 Cocoanut Ave., Sarasota, FL 34234

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]